SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.14% Stake in PROMIS NEUROSCIENCES INC.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 7.14% of PROMIS NEUROSCIENCES INC.'s common shares as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in PROMIS NEUROSCIENCES INC.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 2,334,826 common shares of PROMIS NEUROSCIENCES INC.
• This ownership represents 7.14% of the issuer's common shares outstanding, calculated based on 32,689,190 shares outstanding as of March 29, 2025, as reported in the Issuer's Form 10-K.
• Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, also holds shared voting and dispositive power over the same 2,334,826 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently convey positive or negative sentiment about the company's performance or prospects.

Related Party Transactions

• The Master Fund, a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (7.14%) by Armistice Capital and Steven Boyd provides transparency regarding the company's ownership structure, which can influence investor perception and confidence.

Key Dates

Keywords

PROMIS NEUROSCIENCES INC., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing, Institutional Investor